+31.67% AFME.PA Affluent Medical Euronext 25 Feb 2026: volume surge
The AFME.PA stock surged +31.67% intraday to €3.70 on Euronext on 25 Feb 2026 on a clear volume spike. Trading volume hit 27,635 shares versus an average of 27,900, lifting the share price above its previous year high of €2.95. This intraday move marks a sharp change in market interest for Affluent Medical SA and puts the stock in the high-volume movers category for Europe. We track the price action, fundamentals, technicals, and our model-driven outlook to explain the move and next triggers.
Intraday snapshot: AFME.PA stock performance
AFME.PA traded between €3.48 and €3.87 today, opening at €3.85 and closing near €3.70 at the time of reporting. The stock gained €0.89 on the day, representing a 31.67% rise versus the previous close of €2.81. Market capitalisation stands at €110,426,855.00, with 39,297,813.00 shares outstanding. Relative volume jumped to 6.64x the norm, signalling strong intraday participation on Euronext in the Healthcare devices segment.
Drivers and AFME.PA stock news context
No confirmed company earnings release drove the spike; trading appears driven by retail and momentum flows. The listed earnings date in our file was 30 Sep 2025, so today’s move is independent of a fresh results release. Sector news and sector trading patterns lifted small-cap device names today, while speculative flows supported Affluent Medical’s price breakout. Investors should check the company site and regulatory pages for any late announcements: Affluent Medical website and recent market notices on Euronext Paris source.
Fundamentals and valuation: AFME.PA stock metrics
Affluent Medical reports trailing EPS of -€0.36 and a negative PE ratio of -7.81, reflecting losses. Key valuation metrics include price-to-sales 23.52 and price-to-book 5.24. Cash per share is €0.14 and book value per share is €0.54. The company shows a debt-to-equity ratio of 1.11 and a current ratio of 1.07, indicating modest liquidity with leverage on the balance sheet. These fundamentals frame a higher-risk profile for long-term investors.
Technicals and trading indicators for AFME.PA stock
Technical indicators show heavy short-term momentum and overbought readings. RSI sits at 75.64, ADX at 57.73 signalling a strong trend, and MACD histogram is positive at 0.21. Bollinger upper band is €3.67 versus a middle band of €2.26. On-balance volume reads 904,159.00, and MFI is 94.81, both consistent with heavy buying pressure. Traders should watch for a pullback while momentum remains strong.
Meyka AI rating and AFME.PA stock grade
Meyka AI rates AFME.PA with a score out of 100. Meyka AI rates AFME.PA with a score of 61.37 out of 100, grade B with suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamentals. These grades are model outputs only and not financial advice.
Risks, catalysts and AFME.PA stock outlook
Primary risks include continued negative earnings, stretched valuation metrics, and a long receivables cycle at 325.12 days. Catalysts that could sustain gains are regulatory clearances, trial readouts, or partnerships in the medical devices sector. The Healthcare sector performance today was muted versus Technology, which suggests stock-specific flows fuelled the move. Monitor cash runway, clinical timelines, and any corporate updates for confirmation.
Final Thoughts
AFME.PA stock’s intraday surge to €3.70 on 25 Feb 2026 reflects a high-volume, momentum-driven breakout rather than a confirmed earnings surprise. Short-term technicals point to strong trend strength but overbought readings like RSI 75.64 warn of a possible pullback. Meyka AI’s forecast model projects a short-term monthly level near €3.60 (implying -2.70% from €3.70) and a one-year projection of €1.71, implying -53.87% versus the current price. Price targets for traders: a near-term resistance band around €3.85–€3.87, and a conservative one-year target near €1.71 based on cash flow and earnings trends. Remember these forecasts are model-based projections and not guarantees. Use tight risk controls, watch volume and regulatory updates, and consider the company’s B grade from Meyka AI within a fuller portfolio context. Meyka AI-powered market analysis platform will update if material company news appears.
FAQs
Why did AFME.PA stock move sharply intraday today?
AFME.PA stock rose on heavy volume and momentum trading. There was no confirmed earnings release linked to the spike. Market flows and small-cap device sector interest drove the move, according to intraday volume and technical indicators.
What are the key valuation ratios for AFME.PA stock?
Key metrics: EPS -€0.36, PE -7.81, price-to-sales 23.52, price-to-book 5.24, debt-to-equity 1.11, current ratio 1.07. These ratios reflect loss-making status and stretched valuation.
What does Meyka AI forecast for AFME.PA stock?
Meyka AI’s forecast model projects €3.60 monthly and €1.71 yearly. That implies about -2.70% short-term and -53.87% one-year downside versus €3.70. Forecasts are model projections, not guarantees.
What are the main risks for AFME.PA stock holders?
Main risks include negative earnings, long receivables days (325.12), modest cash per share (€0.14), and leverage. Regulatory or clinical setbacks could trigger further downside for this device company.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.